Crossmark

Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy

Published Online: 2018-06-23

Published Print: 2018-08

Authors

Angeles, Arkhjamil http://orcid.org/0000-0003-1467-0075
Hung, Wayne

Cheung, Winson Y.
Funding

Funding for this research was provided by:

Mach-Gaensslen Foundation of Canada
License Information

Text and Data Mining valid from 2018-06-23
More Information

Article History

Received: 1 June 2018

Accepted: 20 June 2018

First Online: 23 June 2018

Compliance with ethical standards

:

: The authors have no conflicts of interest to declare.

: Ethics approval was obtained from the BCCA Research Ethics Board. Being a retrospective study, formal consent is not required. This article does not contain any studies with animals performed by any of the authors.

Document is current